Please click here for a description of the business.
Please click here for the names of the directors and brief biographical details of each.
Chi-Med is managed by a board of directors (the "Board") which consists of three executive directors, three non-executive directors and three independent non-executive directors (one of whom is senior independent director). The Board is responsible for directing the strategic objectives of Chi-Med and overseeing the management of the business. Directors are charged with the task of promoting the success of Chi-Med and making decisions in the best interest of Chi-Med. The Board, led by the Chairman, approves and monitors the Group's long term objectives and commercial strategies, annual operating and capital expenditure budgets and business plans, evaluating the performance of Chi-Med and supervising the management of Chi-Med.
The Audit Committee
The Audit Committee reviews the Group's preliminary results, interim results and annual financial statements, oversees the relationship between Chi-Med and its external auditors, monitors and reviews the effectiveness of Chi-Med's internal audit function in the context of Chi-Med's overall risk management systems giving due consideration to laws and regulations and the provisions of the UK Corporate Governance Code.
The Audit Committee is chaired by Mr. Graeme Jack and its other members are Mr. Paul Carter and Dr. Karen Ferrante.
The Terms of Reference of the Audit Committee are available here.
The Remuneration Committee
The Remuneration Committee assists the Board in achieving its objective of attracting, retaining and motivating people of the highest calibre and experience needed to shape and execute strategy across the Group's substantial and diverse and international business operations. It ensures that the Group administers a fair and transparent procedure for setting remuneration policies including the assessment of the performance of Executive Directors and senior executives of the Group and determining their remuneration packages.
The Remuneration Committee is chaired by Mr. Paul Carter and its other members are Mr. Simon To and Mr. Graeme Jack.
The Terms of Reference of the Remuneration Committee are available here.
The Technical Committee
The Technical Committee considers from time to time matters relating to the technical aspects of research and development. It invites such executives as it deems appropriate to participate in meetings from time to time.
The Technical Committee is chaired by Dr. Karen Ferrante and its other members are Mr. Paul Carter, Mr. Christian Hogg and Mr. Simon To.
The Terms of Reference of the Technical Committee are available here.
Chi-Med, incorporated in the Cayman Islands, is the holding company of a healthcare group whose main country of operation is China.
As Chi-Med is a Cayman Islands incorporated company, the rights of shareholders may be different from the rights of shareholders in a UK incorporated company. Such rights are regulated by the Memorandum and Articles of Association of Chi-Med and the Companies Law and common law of the Cayman Islands.
Please click for the Memorandum and Articles of Association.
The ordinary shares of Chi-Med were admitted to trading on AIM regulated by the London Stock Exchange.
Chi-Med also has its securities admitted to trading on Nasdaq Stock Market in the form of American Depositary Shares.
Please click here for information on the number of ordinary shares of Chi-Med and details of significant shareholders.
There are no restrictions on the transfer of securities in the Company.
Please click here for access to the Company's annual accounts for the last three years and interim reports since the last annual account.
Please click here to access notifications made by the Company in the past 12 months.
Please click here to read the Statement of Compliance with the UK Corporate Governance Code.
Chi-Med is neither subject to the UK City Code on Takeovers and Mergers nor any other such legislation or code in its country of incorporation or operation.
Please click here to access the Company's advisers.